Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Cash from Financing Activities (2016 - 2025)

BioCorRx's Cash from Financing Activities history spans 16 years, with the latest figure at $810263.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 131.99% year-over-year to $810263.0; the TTM value through Sep 2025 reached $2.0 million, up 61.86%, while the annual FY2024 figure was $1.1 million, 39.51% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $810263.0 at BioCorRx, up from $214229.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $2.2 million in Q1 2021 and bottomed at $59158.0 in Q2 2024.
  • The 5-year median for Cash from Financing Activities is $409087.5 (2023), against an average of $540287.1.
  • The largest annual shift saw Cash from Financing Activities surged 842.13% in 2021 before it tumbled 89.53% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $700000.0 in 2021, then tumbled by 35.05% to $454662.0 in 2022, then decreased by 2.64% to $442649.0 in 2023, then decreased by 24.29% to $335113.0 in 2024, then skyrocketed by 141.79% to $810263.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Cash from Financing Activities are $810263.0 (Q3 2025), $214229.0 (Q2 2025), and $625732.0 (Q1 2025).